Therapeutic patents for chronic heart failure: A review of patent applications from 1996 to 2002

Stefan D. Anker, Ewa A. Jankowska, Darlington O. Okonko

Research output: Contribution to journalArticlepeer-review


Chronic heart failure (CHF) continues to represent an enormous clinical challenge. Despite the advent of angiotensin-converting enzyme (ACE) inhibitors and β-blockers, the quality of life and survival of affected individuals remains unacceptably poor. Therefore, novel therapeutic approaches which may confer incremental prognostic benefits in CHF are urgently needed. In this article, a selection of the patents published between 1996 and 2002 that aim to ameliorate CHF using the following therapeutic modalities are reviewed: neurohormonal modulators, antiarrhythmic agents, antianaemia therapies, anabolic compounds, insulin sensitivity enhancers, xanthine oxidase inhibitors, immune modulators, antiapoptotic agents, stem cell therapy, gene therapy and other miscellaneous agents. The authors also attempt to highlight, where possible, the current evidence for the efficacy of such proposed strategies. 2004

Original languageEnglish
Pages (from-to)639-654
Number of pages16
JournalExpert Opinion on Therapeutic Patents
Issue number5
Publication statusPublished - May 2004


  • Cardiac cachexia
  • Cardiomyopathy
  • Drug therapy
  • Gene therapy
  • Heart failure
  • Stem cells

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology
  • Law


Dive into the research topics of 'Therapeutic patents for chronic heart failure: A review of patent applications from 1996 to 2002'. Together they form a unique fingerprint.

Cite this